Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis magnesium mystery: pilot study seeks answers

NCT ID NCT07565779

Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adjusting the amount of magnesium in the dialysis fluid could help keep blood magnesium levels in a healthy range for people with kidney failure on hemodialysis. Fifty-four adults took part in this pilot crossover trial. The goal was to gather information, not to treat or cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

Jan 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent must be obtained prior to any screening procedures 2. Clinically stable during two months prior to the study. This will be based upon clinical judgement. 3. On stable blood pressure medication 4 weeks prior to the study 4. Dialysis with a K3 dialysate 5. Adequate double-needle dialysis access (fistula or catheter) 6. Able to fill questionnaire/symptom score Exclusion Criteria: 1. Predialysis calcium \<1,9mmol/L during baseline 2. Magnesium predialysis \>1,45mmol/L during baseline 3. Patient has a history of child C liver cirrhosis 4. Coronary intervention \<3 months before randomization 5. Hospitalization \<2 months before randomization 6. Uncontrolled predialysis hypertension \>160/90mmHg despite 4 antihypertensive drugs 7. Predialysis blood pressure \<90mmHg during baseline visit 8. History of dialysis access related problems \<1 month before the randomization 9. Chronic Atrial fibrillation 10. NYHA class 4 heart failure 11. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dialysis; complications are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure Muscle Cramp

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dialysis; complications

Contacts and locations

Locations

  • AZ groeninge

    Kortrijk, West-Vlaanderen, 3621, Belgium

  • Azorg

    Aalst, Oost-Vlaanderen, Belgium

  • UZ Brussel

    Brussels, Brussels Capital, 1000, Belgium

  • UZ Leuven

    Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.